Skip to main content

Advertisement

SpringerLink
Log in

Smoking Cessation: Significance and Implications for Children

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

A number of people in the USA who are still current smokers remain a staggering figure. Although this number continues to decrease, there is still a considerable amount of second-hand smoke. More importantly and for the purpose of this review, the detrimental effects of passive smoke in children is significant. We will not review the specific health effects of passive smoke, but for pediatricians, in particular, it is important to place in perspective programs that are available to influence the parents of children to stop smoking. Indeed, approximately 25% of all children aged 3–11 live in a household with at least one smoker. Despite the increasing number of communities in the states that have instituted restrictions or complete bans on smoking in the workplace and in many public areas, the principal site of smoking remains the home.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (2005) Cigarette smoking among adults—United States, 2004. Morb Mort Wkly Rep 54:1121–1124

    Google Scholar 

  2. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaén CR, Kottke TE, Lando HA, Mecklenburg RE, Mullen PD, Nett LM, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME (2000) Treating tobacco use and dependence. A clinical practice guideline. AHCPR Publication no. 00-0032. US Department of Health and Human Services, Rockville, MD

    Google Scholar 

  3. US Environmental Protection Agency (1992) Respiratory health effects of passive smoking: lung cancer and other disorders. Office of Health and Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DC

    Google Scholar 

  4. Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF (2006) Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988–2002. Environ Health Perspect 114:853–858

    Article  PubMed  CAS  Google Scholar 

  5. US Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA

    Google Scholar 

  6. Kum-Nji P, Meloy L, Herrod HG (2006) Environmental tobacco smoke exposure: prevalence and mechanisms of causation of infections in children. Pediatrics 117:1745–1754

    PubMed  Google Scholar 

  7. Centers for Disease Control and Prevention (2005) Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. Morb Mort Wkly Rep 54:625–628

    Google Scholar 

  8. Ezzati M, Lopez AD (2003) Estimates of global mortality attributable to smoking in 2000. Lancet 362:847–852

    PubMed  Google Scholar 

  9. Bjartveit K, Tverdal A (2005) Health consequences of smoking 1–4 cigarettes per day. Tob Control 14:315–320

    PubMed  CAS  Google Scholar 

  10. Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328:1519

    PubMed  Google Scholar 

  11. Miller T, Rauh VA, Glied SA, Hattis D, Rundle A, Andrews H, Perera F (2006) The economic impact of early life environmental tobacco smoke exposure: early intervention for developmental delay. Environ Health Perspect 114:1585–1588

    PubMed  Google Scholar 

  12. Anthonisen NR, Connett JE, Enright PL, Manfreda J (2002) Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166:333–339

    PubMed  Google Scholar 

  13. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142:233–239

    PubMed  Google Scholar 

  14. Pelkonen M, Tukiainen H, Tervahauta M, Notkola IL, Kivelä SL, Salorinne Y, Nissinen A (2000) Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax 55:746–750

    PubMed  CAS  Google Scholar 

  15. Godtfredsen NS, Vestbo J, Osler M, Prescott E (2002) Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 57:967–972

    PubMed  CAS  Google Scholar 

  16. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP (2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161:381–390

    PubMed  CAS  Google Scholar 

  17. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A (2001) Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 56:703–707

    PubMed  CAS  Google Scholar 

  18. Murray RP, Anthonisen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, Nides MA (1998) Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol 51:1317–1326

    PubMed  CAS  Google Scholar 

  19. Hughes JR, Higgins ST, Bickel WK (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89:1461–1470

    PubMed  CAS  Google Scholar 

  20. American Psychiatric Association (2003) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  21. Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J, Baker TB (1996) Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology (Berl) 128:130–138

    CAS  Google Scholar 

  22. Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, Kligman E, Cook G (1997) Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 5:54–64

    PubMed  CAS  Google Scholar 

  23. Hatsukami D, Skoog K, Allen S, Bliss R (1995) Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Exp Clin Psychopharmacol 3:163–173

    Google Scholar 

  24. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH (2004) Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol 72:1136–1143

    PubMed  Google Scholar 

  25. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR (2002) Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162:1267–1276

    PubMed  CAS  Google Scholar 

  26. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, Feyerabend C (1992) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324–329

    PubMed  CAS  Google Scholar 

  27. Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240

    PubMed  CAS  Google Scholar 

  28. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL (2000) Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 66:553–558

    PubMed  CAS  Google Scholar 

  29. Guthrie SK, Ni L, Zubieta JK, Teter CJ, Domino EF (2004) Changes in craving for a cigarette and arterial nicotine plasma concentrations in abstinent smokers. Prog Neuropsychopharmacol Biol Psychiatry 28:617–623

    PubMed  CAS  Google Scholar 

  30. Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M (1997) A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 106:104–116

    PubMed  CAS  Google Scholar 

  31. Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C (2004) Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 172:271–276

    CAS  Google Scholar 

  32. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379

    PubMed  CAS  Google Scholar 

  33. Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314

    PubMed  Google Scholar 

  34. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54:65–71

    PubMed  CAS  Google Scholar 

  35. Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743–751

    PubMed  CAS  Google Scholar 

  36. Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Léonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrié P, Scatton B (2003) SSR591813, a novel selective and partial α4β2. nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 306:407–420

    PubMed  CAS  Google Scholar 

  37. Mansbach RS, Chambers LK, Rovetti CC (2000) Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berl) 148:234–242

    CAS  Google Scholar 

  38. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177

    PubMed  CAS  Google Scholar 

  39. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:1029–1032

    PubMed  CAS  Google Scholar 

  40. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446

    PubMed  CAS  Google Scholar 

  41. Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16:905–908

    PubMed  CAS  Google Scholar 

  42. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736

    PubMed  CAS  Google Scholar 

  43. Glautier S (2004) Measures and models of nicotine dependence: positive reinforcement. Addiction 99(Suppl 1):30–50

    PubMed  Google Scholar 

  44. Eissenberg T (2004) Measuring the emergence of tobacco dependence: the contribution of negative reinforcement models. Addiction 99(Suppl 1):5–29

    PubMed  Google Scholar 

  45. Brandon TH, Herzog TA, Irvin JE, Gwaltney CJ (2004) Cognitive and social learning models of drug dependence: implications for the assessment of tobacco dependence in adolescents. Addiction 99(Suppl 1):51–77

    PubMed  Google Scholar 

  46. Stead LF, Lancaster T (2005) Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev, Issue 2, Art. no. CD001007.pub2. Date of most recent substantive amendment: 16 February 2005

  47. Lancaster T, Stead LF (2005) Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev, Issue 2, Art. no. CD001292.pub2. Date of most recent substantive amendment: 08 February 2005

  48. Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, Issue 3, Art. no. CD000146.pub2. Most recent substantive amendment: 07 April 2004

  49. Hughes JR, Burns DM (2000) Impact of medications on smoking cessation. In: Shopland DR, Burns DM, Amacher RH, Ruppert W (eds) Population based smoking cessation: Proceedings of a conference on what works to influence cessation in the general population. Smoking and Tobacco Control Monograph no. 12, NIH Publications, no. 00-4892, Bethesda, MD, pp 155–164

  50. Hughes JR, Shiffman S, Callas P, Zhang J (2003) A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12:21–27

    PubMed  CAS  Google Scholar 

  51. Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115

    PubMed  CAS  Google Scholar 

  52. Sobue S, Sekiguchi K, Kikkawa H, Irie S (2005) Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch. J Clin Pharmacol 45:1391–1399

    PubMed  CAS  Google Scholar 

  53. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67:479–482

    PubMed  CAS  Google Scholar 

  54. Homsy W, Yan K, Houle JM, Besner JG, Gossard D, Pierce CH, Caillé G (1997) Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. J Clin Pharmacol 37:728–736

    PubMed  CAS  Google Scholar 

  55. Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J (2005) Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction 100:1720–1730

    PubMed  Google Scholar 

  56. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033–2038

    PubMed  CAS  Google Scholar 

  57. West R, Shiffman S (2001) Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology (Berl) 155:115–122

    CAS  Google Scholar 

  58. Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP (1998) Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 140:98–104

    CAS  Google Scholar 

  59. Burton SM, Tiffany ST (1997) The effect of alcohol consumption on imaginal and in vivo manipulations of smoking urges. Addiction 92:15–26

    PubMed  CAS  Google Scholar 

  60. Maude-Griffin R, Tiffany ST (1996) Production of smoking urges through imagery: the impact of affect and smoking abstinence. Exp Clin Psychopharmacol 4:198–208

    Google Scholar 

  61. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl) 166:343–350

    CAS  Google Scholar 

  62. Fagerström KO, Schneider NG, Lunell E (1993) Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl) 111:271–277

    Google Scholar 

  63. Swan GE, Ward MM, Jack LM (1996) Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav 21:481–490

    PubMed  CAS  Google Scholar 

  64. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691

    PubMed  CAS  Google Scholar 

  65. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571–1575

    PubMed  CAS  Google Scholar 

  66. Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G (2006) Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 7:147–154

    PubMed  CAS  Google Scholar 

  67. Wetter DW, Fiore MC, Baker TB, Young TB (1995) Tobacco withdrawal and nicotine replacement influence objective measures of sleep. J Consult Clin Psychol 63:658–667

    PubMed  CAS  Google Scholar 

  68. Greenland S, Satterfield MH, Lanes SF (1998) A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 18:297–308

    PubMed  CAS  Google Scholar 

  69. Medioni J, Berlin I, Mallet A (2005) Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach. Addiction 100:247–254

    PubMed  Google Scholar 

  70. Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM, Lindgren P, Connett JE (1995) Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol 63:60–69

    PubMed  CAS  Google Scholar 

  71. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 318:285–288

    PubMed  CAS  Google Scholar 

  72. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, Steinberg C (1995) Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90:1671–1682

    PubMed  CAS  Google Scholar 

  73. Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI (1999) The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 28:113–118

    PubMed  CAS  Google Scholar 

  74. Joseph AM, Fu SS (2003) Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 45:429–441

    PubMed  CAS  Google Scholar 

  75. Wilhelm K, Wedgwood L, Niven H, Kay-Lambkin F (2006) Smoking cessation and depression: current knowledge and future directions. Drug Alcohol Rev 25:97–107

    PubMed  Google Scholar 

  76. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives (2000) A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service Report. JAMA 283:3244–3254

    Google Scholar 

  77. Hughes J, Stead L, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database Syst Rev, Issue 4, Art. no. CD000031

  78. Sánchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489

    PubMed  Google Scholar 

  79. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88–92

    PubMed  CAS  Google Scholar 

  80. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327

    PubMed  CAS  Google Scholar 

  81. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287–291

    PubMed  CAS  Google Scholar 

  82. Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev Issue 3, Art. no. CD000058. Date of most recent substantive amendment: 12 May 2004

  83. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT (2005) Varenicline: an α4β2. nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477

    PubMed  CAS  Google Scholar 

  84. Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 70:801–805

    PubMed  CAS  Google Scholar 

  85. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW (2006) Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121–130

    PubMed  CAS  Google Scholar 

  86. Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH (2006) Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 46:1439–1448

    PubMed  CAS  Google Scholar 

  87. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166:1571–1577

    PubMed  CAS  Google Scholar 

  88. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR (2006) Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561–1568

    PubMed  Google Scholar 

  89. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63

    PubMed  CAS  Google Scholar 

  90. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55

    PubMed  CAS  Google Scholar 

  91. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71

    PubMed  CAS  Google Scholar 

  92. Klesges RC, Johnson KC, Somes G (2006) Varenicline for smoking cessation: definite promise, but no panacea. JAMA 296:94–95

    PubMed  Google Scholar 

  93. Pfizer (2006). Chantixä (varenicline) tablets. Available at: www.pfizer.com/pfizer/download/uspi_chantix.pdf. Accessed on: June 2

  94. Strasser AA, Pickworth WB, Patterson F, Lerman C (2004) Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 13:1800–1804

    PubMed  CAS  Google Scholar 

  95. Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70:216–227

    PubMed  Google Scholar 

  96. da Costa CL, Younes RN, Lourenço MT (2002) Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122:403–408

    PubMed  Google Scholar 

  97. Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD (2001) Bupropion for smoking cessation: predictors of successful outcome. Chest 119:1357–1364

    PubMed  CAS  Google Scholar 

  98. Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A (2000) Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 68:883–889

    PubMed  CAS  Google Scholar 

  99. Tønnesen P, Mikkelsen KL (2000) Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 16:717–722

    PubMed  Google Scholar 

  100. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A (1999) Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol 7:226–233

    PubMed  CAS  Google Scholar 

  101. Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ (1997) Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 22:521–533

    PubMed  CAS  Google Scholar 

  102. Gulliver SB, Hughes JR, Solomon LJ, Dey AN (1995) An investigation of self-efficacy, partner support and daily stresses as predictors of relapse to smoking in self-quitters. Addiction 90:767–772

    PubMed  CAS  Google Scholar 

  103. Hall SM, Muñoz RF, Reus VI (1994) Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 62:141–146

    PubMed  CAS  Google Scholar 

  104. Killen JD, Fortmann SP, Kraemer HC, Varady A, Newman B (1992) Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol 60:797–801

    PubMed  CAS  Google Scholar 

  105. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J (2003) Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med 114:555–562

    PubMed  Google Scholar 

  106. Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 5:137–142

    PubMed  CAS  Google Scholar 

  107. Doherty K, Kinnunen T, Militello FS, Garvey AJ (1995) Urges to smoke during the first month of abstinence: relationship to relapse and predictors. Psychopharmacology (Berl) 119:171–178

    CAS  Google Scholar 

  108. Hall SM, Muñoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, Hartz DT (1996) Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 64:1003–1009

    PubMed  CAS  Google Scholar 

  109. Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–690

    PubMed  CAS  Google Scholar 

  110. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219–223

    PubMed  CAS  Google Scholar 

  111. Wetter DW, Kenford SL, Smith SS, Fiore MC, Jorenby DE, Baker TB (1999) Gender differences in smoking cessation. J Consult Clin Psychol 67:555–562

    PubMed  CAS  Google Scholar 

  112. Rose JE, Behm FM, Westman EC (1998) Nicotinemecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331–343

    PubMed  CAS  Google Scholar 

  113. Scharf D, Shiffman S (2004) Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 99:1462–1469

    PubMed  Google Scholar 

  114. Perkins KA (1996) Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharmacol 4:166–177

    CAS  Google Scholar 

  115. Perkins KA, Donny E, Caggiula AR (1999) Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1:301–315

    PubMed  CAS  Google Scholar 

  116. Wetter DW, Fiore MC, Young TB, McClure JB, de Moor CA, Baker TB (1999) Gender differences in response to nicotine replacement therapy: objective and subjective indexes of tobacco withdrawal. Exp Clin Psychopharmacol 7:135–144

    PubMed  CAS  Google Scholar 

  117. Meyers AW, Klesges RC, Winders SE, Ward KD, Peterson BA, Eck LH (1997) Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol 65:448–452

    PubMed  CAS  Google Scholar 

  118. Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Croghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL (2006) The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav 31:1144–1152

    PubMed  Google Scholar 

  119. Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, Ray JW, Shadish WR (1997) How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65:286–291

    PubMed  CAS  Google Scholar 

  120. Filozof C, Fernández Pinilla MC, Fernández-Cruz A (2004) Smoking cessation and weight gain. Obes Rev 5:95–103

    PubMed  CAS  Google Scholar 

  121. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202

    PubMed  CAS  Google Scholar 

  122. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD (2001) Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 135:423–433

    PubMed  CAS  Google Scholar 

  123. Li MD, Ma JZ, Beuten J (2004) Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 66:382–392

    PubMed  CAS  Google Scholar 

  124. Tyndale RF (2003) Genetis of alcohol and tobacco use in humans. Ann Med 35:94–121

    PubMed  CAS  Google Scholar 

  125. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615–626

    PubMed  CAS  Google Scholar 

  126. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451–2458

    PubMed  CAS  Google Scholar 

  127. Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, Ueki R, Kawashima K, Hara H, Fujio Y, Azuma J (2006) CYP2A6. polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6:115–119

    PubMed  CAS  Google Scholar 

  128. Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229–239

    PubMed  CAS  Google Scholar 

  129. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231–242

    PubMed  CAS  Google Scholar 

  130. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83–90

    PubMed  CAS  Google Scholar 

  131. Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989–990

    PubMed  Google Scholar 

  132. Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R, Olmstead RE, Cortner C (2005) Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berl) 182:545–550

    CAS  Google Scholar 

  133. Schneider NG, Olmstead RE, Nides M, Mody FV, Otte-Colquette P, Doan K, Patel S (2004) Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 28:72–86

    PubMed  Google Scholar 

  134. Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, Herrero LA, Krishen A, Sweeney A, Buaron K, Metz A (2001) Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 69:438–444

    PubMed  CAS  Google Scholar 

  135. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1995) Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 311:363–366

    PubMed  CAS  Google Scholar 

  136. Hughes JR, Grass JA, Pillitteri JL (2000) Treatment resistant smokers: a pilot study of nicotine nasal spray and inhaler. J Addict Dis 19:95–100

    PubMed  CAS  Google Scholar 

  137. Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, Nides MA, Ascher JA, Johnston JA (2002) Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav 26:213–220

    PubMed  Google Scholar 

  138. Shiffman S, Dresler CM, Rohay JM (2004) Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99:83–92

    PubMed  Google Scholar 

  139. Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambkin FJ, Wye P, Walsh RA, Pulver LJ, Richmond R, Belcher J, Wilhelm K, Wodak A (2006) Where there’s smoke, there’s fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug Alcohol Rev 25:85–96

    PubMed  Google Scholar 

  140. Ahluwalia JS, McNagny SE, Clark WS (1998) Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med 13:1–8

    PubMed  CAS  Google Scholar 

  141. Winickoff JP, Buckley VJ, Palfrey JS, Perrin JM, Rigotti NA (2003) Intervention with parental smokers in an outpatient pediatric clinic using counseling and nicotine replacement. Pediatrics 112:1127–1133

    PubMed  Google Scholar 

  142. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29:1–9

    PubMed  Google Scholar 

  143. Gilliam LK, Jensen RA, Yang P, Weigle DS, Greenbaum CJ, Pihoker C (2006) Evaluation of leptin levels in subjects at risk for type 1 diabetes. J Autoimmun 26:133–137

    PubMed  CAS  Google Scholar 

  144. Gleicher N, Weiner R, Vietzke M (2006) The impact of abnormal autoimmune function on reproduction: Maternal and fetal consequences. J Autoimmun 27:161–165

    PubMed  CAS  Google Scholar 

  145. Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75

    PubMed  CAS  Google Scholar 

  146. Khan NA, Yessoufou A, Kim M, Hichami A (2006) N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J Autoimmun 26:268–277

    PubMed  CAS  Google Scholar 

  147. Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, Shoenfeld Y, Szegedi G (2006) Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27:211–217

    PubMed  CAS  Google Scholar 

  148. Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28:129–133

    PubMed  CAS  Google Scholar 

  149. Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A (2006) Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 26:66–71

    PubMed  CAS  Google Scholar 

  150. Zlacka D, Vavrincova P, Hien Nguyen TT, Hromadnikova I (2006) Frequency of anti-hsp60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 27:81–88

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutrition, Division of Rheumatology/Allergy and Clinical Immunology, Davis School of Medicine, University of California, Davis, CA, 95616, USA

    Andrea T. Borchers, Carl. L. Keen & M. Eric Gershwin

Authors
  1. Andrea T. Borchers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl. L. Keen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Eric Gershwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Eric Gershwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borchers, A.T., Keen, C.L. & Gershwin, M.E. Smoking Cessation: Significance and Implications for Children. Clinic Rev Allerg Immunol 34, 231–249 (2008). https://doi.org/10.1007/s12016-007-8040-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8040-3

Keywords

Search

Navigation